BioNxt Solutions Reports Progress on BNT23001 Development for Multiple Sclerosis Treatment
VANCOUVER, BC / ACCESSWIRE / December 9, 2024 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT), a bioscience company specializing in advanced drug delivery systems, has achieved key milestones in the development of BNT23001, its proprietary sublingual thin-film (OFD) formulation of Cladribine for the treatment of Multiple Sclerosis (MS). These achievements in 2024 lay the groundwork for clinical trials and regulatory submissions in 2025, reinforcing BioNxt's commitment to advancing patient-centric therapeutic solutions.
2024 Milestones: Establishing a Strong Foundation for Cladribine Thin-Film Development
Preclinical Success: BNT23001 demonstrated high absorption rates of Cladribine through sublingual delivery in pharmacokinetic (PK) studies conducted in animal models. These studies confirmed the product's bioequivalence to the originator therapy, Mavenclad®, and validated the thin-film's rapid absorption and safety profile. Toxicity studies further demonstrated no adverse local effects, highlighting the viability of the sublingual delivery approach.
Advancements in Manufacturing: BioNxt successfully transferred the BNT23001 production process to its GMP-certified manufacturing partner, Gen-Plus GmbH & Co KG in Munich (Germany), ensuring readiness for clinical batch production. This milestone supports the Company's plan to initiate clinical trials in 2025 with reliable, high-quality product supply.
Strengthened Intellectual Property Position: A favorable International Preliminary Report on Patentability (IPRP) confirmed BNT23001's novelty, inventive step, and industrial applicability, underscoring its unique value in MS treatment. The Company has initiated patent nationalization in major jurisdictions, including Europe, the United States, and Canada, with patent grants anticipated in several regions by mid-2025.
2025 Roadmap: Advancing BNT23001 into Clinical Trials
Manufacturing Clinical Batches: BioNxt will complete GMP manufacturing and Qualified Person (QP) release of clinical trial batches in the second quarter of 2025. This step is critical for the successful initiation of human studies.
Regulatory Filings and Approvals: The Company plans to submit the Investigational Medicinal Product Dossier (IMPD) to European regulatory authorities by mid-2025, paving the way for clinical trial approval. These regulatory submissions will include data from preclinical studies and stability assessments conducted at the manufacturing site.
Clinical Study to Validate Performance: BioNxt aims to launch a pilot clinical study in the latter half of 2025. This trial will compare the efficacy, bioavailability, and safety of BNT23001 to Mavenclad®, the originator tablet product, positioning the thin-film formulation as a patient-friendly alternative.
Ongoing Patent Protection: In addition to continuing the patent nationalization process, BioNxt expects granted patents in key regions to strengthen its intellectual property portfolio and provide competitive advantages as the product moves toward commercialization.
BNT23001: Advancing Toward Clinical Validation for MS Treatment
BNT23001 offers a novel approach to MS management by addressing limitations in traditional oral therapies. Its sublingual thin-film format provides:
• Convenience: Easy-to-use and portable, ideal for patients with difficulty swallowing or active lifestyles.
• Rapid Absorption: Direct delivery through the sublingual mucosa for faster therapeutic action.
• Improved Compliance: A patient-friendly alternative designed to enhance adherence to prescribed regimens.
By delivering these advantages, BNT23001 aligns with BioNxt's mission to improve outcomes for patients living with chronic diseases like MS.
About BioNxt Solutions Inc.
BioNxt Solutions Inc. is a bioscience innovator focused on next-generation drug delivery technologies, diagnostic screening systems, and active pharmaceutical ingredient development. The Company's proprietary platforms-Sublingual (Thin-Film), Transdermal (Skin Patch), and Oral (Enteric-Coated Tablets)-target key therapeutic areas, including autoimmune diseases, neurological disorders, and longevity.
With research and development operations in North America and Europe, BioNxt is advancing regulatory approvals and commercialization efforts, primarily focused on European markets. BioNxt is committed to improving healthcare by delivering precise, patient-centric solutions that enhance treatment outcomes worldwide.
BioNxt is listed on the Canadian Securities Exchange: BNXT, OTC Markets: BNXTF and trades in Germany under WKN: A3D1K3. To learn more about BioNxt, please visit www.bionxt.com.
Investor Relations & Media Contact
Hugh Rogers, Co-Founder, CEO and Director
Email: investor.relations@bionxt.com
Phone: +1 780-818-6422
Web: www.bionxt.com
LinkedIn: https://www.linkedin.com/company/bionxt-solutions
Instagram: https://www.instagram.com/bionxt
Cautionary Statement Regarding "Forward-Looking" Information
This press release contains forward-looking statements within the meaning of applicable securities laws, including statements regarding the development, testing, regulatory approval, and commercialization of BNT23001, as well as projected milestones for 2025. These statements are based on current expectations and assumptions but involve risks and uncertainties that could cause actual results to differ materially. These risks include clinical trial outcomes, regulatory delays, manufacturing challenges, intellectual property issues, market competition, and changes in laws or market conditions. The Company undertakes no obligation to update or revise forward-looking statements, except as required by law. For more information, refer to the "Risk Factors" section of the Company's filings at www.sedarplus.ca.
Trademarks: Mavenclad® is a registered trademark of EMD Serono, Inc. BioNxt Solutions Inc. is not affiliated with or endorsed by EMD Serono.
SOURCE: BioNxt Solutions Inc.
View the original press release on accesswire.com
BioNxt Solutions Inc.
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Clean Air Metals Files Interim Financial Statements for the Nine Months Ended October 31, 202530.12.2025 03:20:00 CET | Press release
THUNDER BAY, ON / ACCESS Newswire / December 29, 2025 / Clean Air Metals Inc. ("Clean Air Metals" or the "Company") (TSXV:AIR)(FRA:CKU)(OTCQB:CLRMF) announces that it has filed its unaudited consolidated interim financial statements and management's discussion and analysis for the nine-month period ended October 31, 2025, available for viewing on www.sedarplus.ca. Financial Highlights Total assets as at October 31, 2025 of $36,602,553 Total cash as at October 31, 2025 of $1,643,422 Working capital deficiency as at October 31, 2025 of $1,746,454 Shareholder's equity as at October 31, 2025 of $33,030,843 During the nine months ended October 31, 2025, the Company incurred $1,046,223 in cost for exploration activities at the TBN project. Key activities of the Company's management team this quarter included the completion of the initial drilling of the first step-out exploration target within the Escape down-plunge area, resulting in a mineralized intersection 400m from the known resource.
EESystem Files for Preliminary Injunction to Block Unauthorized Use of Proprietary Wellness Technology29.12.2025 17:15:00 CET | Press release
Legal action seeks to halt Jason Shurka and The Light System, Inc. from misappropriating EES intellectual property LAS VEGAS, NV / ACCESS Newswire / December 29, 2025 / Energy Enhancement System, LLC (EES), a global provider of advanced wellness technology, has taken decisive legal action to protect its proprietary innovations and the integrity of its licensed network. On December 22, 2025, EES filed a Motion for Preliminary Injunction in the U.S. District Court for the District of Nevada. The motion seeks to immediately enjoin defendants Jason Shurka and The Light System, Inc., operating via thelightsystems.com and unifydhealing.com, with events and personal bio promoted on jasonshurka.com, from the unauthorized use of EES's intellectual property. This filing is a critical step in defending the authenticity of the EE System technology, which powers an extensive global network with thousands of installations worldwide. The motion is supported by detailed evidence alleging contractual b
Launch of the 8th Global Conference on Occupational Safety and Health (GOSH 8) in RIYADH, SA - 202628.12.2025 13:30:00 CET | Press release
RIYADH, SA / ACCESS Newswire / December 28, 2025 / His Excellency Eng. Ahmed bin Sulaiman Al‑Rajhi, Minister of Human Resources and Social Development and Chairman of the National Council for Occupational Safety and Health, announced the launch of the 8th Global Conference on Occupational Safety and Health (GOSH8), scheduled to be held in 2026 under the theme "Sustainable Safety for a Prosperous Future." The conference will take place from 27 to 29 April 2026 at the Hilton Hotel in Riyadh, Saudi Arabia. During the announcement, His Excellency also inaugurated the official website of the 8th Global Conference on Occupational Safety and Health, which enables specialists and interested participants to register for the conference and access full details, including key themes, topics, and accompanying activities. The conference continues to play a leading role as an international scientific platform, dedicated to exploring the future of occupational safety and health, discussing global labo
Loar Holdings Inc. Announced The Completion of its Acquisition of LMB Fans & Motors26.12.2025 14:00:00 CET | Press release
WHITE PLAINS, NEW YORK / ACCESS Newswire / December 26, 2025 / Loar Holdings Inc. (NYSE:LOAR) ("Loar," "we," "our," or "the Company") today announced the completion of its acquisition of LMB Fans & Motors ("LMB") for €367 million, plus the assumption of debt, paid in cash at closing. Founded more than 60 years ago, LMB is a global leader in designing and manufacturing customized, high-performance fans and motors. With decades of expertise and nearly 100% of its revenue derived from proprietary designs, LMB offers over 2,000 unique products, including fans, blowers, motors, and specialized rotating machines. Its fans and brushless motors are widely used across aerospace and defense platforms. LMB employs more than 75 team members worldwide, including those at its headquarters and manufacturing facility in Malemort-sur-Corrèze, France. The transaction was completed following clearance under the French foreign direct investment screening procedure by the Ministry of Economy and Finance. L
SK tes Announces Grand Opening of New Shannon Facility, Marking a Milestone for Sustainable Technology in Ireland22.12.2025 15:00:00 CET | Press release
SHANNON, IE / ACCESS Newswire / December 22, 2025 / SK tes, a global leader in secure technology lifecycle and IT asset disposition (ITAD) services, is delighted to announce the grand opening of its state-of-the-art facility in Shannon, County Clare. The opening event, to be held on Jan. 15, 2026, marks the culmination of a journey that began with the company's announcement in 2025 of its plans to establish a purpose-built facility in one of Ireland's fastest-growing technology regions. The grand opening will be hosted by Jin Mo Lee, SK tes Group CEO at SK tes and guest of honor, Minister Timmy Dooley will cut the ribbon to officially open the site. Minister Dooley, a Clare native, serves as Minister of State for Climate, Energy and the Environment. Minister Dooley's leadership in climate, energy, and environmental policy is especially relevant as Ireland continues to attract major global data center infrastructure and technology companies, while placing increased emphasis on sustainab
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom